|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Conjugate||Alexa Fluor® 700|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
The Alexa Fluor® 700 dye conjugate provides an excellent spectral match to the common long-wavelength excitation sources, with a high extinction coefficient.
The CD4 antigen is involved in the recognition of the type II MHC antigen. It is also a receptor for HIV. It is present on most T helper cells and normal thymocytes. The cytoplasmic portion of CD4 is associated with p56lck tyrosine kinase. CD4 expression is commonly found in human lymph nodes and tonsils. CD44 is a type 1 transmembrane glycoprotein also known as Phagocytic Glycoprotein-1 (pgp-1) and HCAM. CD44 is the receptor for hyaluronate and exists as a large number of different isoforms due to alternative RNA splicing. The major isoform expressed on lymphocytes, myeloid cells, and erythrocytes is a glycosylated type 1 transmembrane protein. Other isoforms contain glycosaminoglycans and are expressed on hematopoietic and non-hematopoietic cells. CD44 is involved in adhesion of leukocytes to endothelial cells, stromal cells, and the extracellular matrix.
Analyte Specific Reagent
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
MHCD0429 was used in flow cytometry to characterize therapy-induced T cell reactivity using a panel of 45 melanoma-associated CD8(+) T cell epitopes.
|Kvistborg P,Shu CJ,Heemskerk B,Fankhauser M,Thrue CA,Toebes M,van Rooij N,Linnemann C,van Buuren MM,Urbanus JH,Beltman JB,Thor Straten P,Li YF,Robbins PF,Besser MJ,Schachter J,Kenter GG,Dudley ME,Rosenberg SA,Haanen JB,Hadrup SR,Schumacher TN||Oncoimmunology (1:409)||2012|